Relief of Intractable Posthypoxic Myoclonus After Administration of Agomelatine
- 1 September 2012
- journal article
- case report
- Published by Wolters Kluwer Health in Clinical Neuropharmacology
- Vol. 35 (5) , 258-259
Abstract
Chronic posthypoxic myoclonus is characterized by myoclonic jerks that are specifically triggered by action. It is a rare but devastating sequela of hypoxic encephalopathy. We report a 42-year-old female patient with treatment-resistant chronic posthypoxic myoclonus, which improved with administration of the drug agomelatine. We suggest that agomelatine could represent a useful therapeutic option in the treatment of chronic posthypoxic myoclonus.Keywords
This publication has 10 references indexed in Scilit:
- Novel melatonin-based therapies: potential advances in the treatment of major depressionThe Lancet, 2011
- Posthypoxic Myoclonus (Lance-Adams Syndrome) Treated With LacosamideClinical Neuropharmacology, 2010
- Dramatic Effect of Levetiracetam on Posthypoxic Myoclonus: Difficult Weaning From Mechanical VentilationClinical Neuropharmacology, 2009
- A Patient with Intractable Posthypoxic Myoclonus (Lance-Adams Syndrome) Treated with Sodium OxybateAnaesthesia and Intensive Care, 2009
- The metabolic topography of posthypoxic myoclonusNeurology, 2004
- The Novel Melatonin Agonist Agomelatine (S20098) Is an Antagonist at 5-Hydroxytryptamine2C Receptors, Blockade of Which Enhances the Activity of Frontocortical Dopaminergic and Adrenergic PathwaysThe Journal of Pharmacology and Experimental Therapeutics, 2003
- The clinical spectrum of posthypoxic myoclonusMovement Disorders, 2000
- Animal model of posthypoxic myoclonusNeurology, 1999
- Hypoxia versus ischemiaNeurology, 1999
- THE SYNDROME OF INTENTION OR ACTION MYOCLONUS AS A SEQUEL TO HYPOXIC ENCEPHALOPATHYBrain, 1963